Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Published:2013-09-12 Issue:11 Volume:122 Page:1891-1899
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ferrajoli Alessandra¹,Shanafelt Tait D.²,Ivan Cristina³,Shimizu Masayoshi⁴,Rabe Kari G.⁵,Nouraee Nazila⁴,Ikuo Mariko⁴⁶,Ghosh Asish K.²,Lerner Susan¹,Rassenti Laura Z.⁷,Xiao Lianchun⁸,Hu Jianhua⁸,Reuben James M.⁹,Calin Steliana⁹,You M. James⁹,Manning John T.⁹,Wierda William G.¹,Estrov Zeev¹,O’Brien Susan¹,Kipps Thomas J.⁷,Keating Michael J.¹,Kay Neil E.²,Calin George A.¹⁴⁵

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN;

3. Center for RNA Interference and Non-Coding RNAs, and

4. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;

5. Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN;

6. Graduate School of Pharmaceutical Sciences, Tokyo University, Tokyo, Japan;

7. University of California, San Diego, Moores Cancer Center, La Jolla, California; and

8. Department of Biostatistics and

9. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points miR-155 levels are significantly and increasingly overexpressed as normal B cells progress to MBL and to CLL. Plasma levels of miR-155 before treatment were significantly lower in patients with CLL who experienced complete response than in all others.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/11/1891/1331075/1891.pdf

Reference40 articles.

1. microRNAs: tiny regulators with great potential.;Ambros;Cell,2001

2. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes.;Calin;Blood,2009

3. MicroRNAs: genomics, biogenesis, mechanism, and function.;Bartel;Cell,2004

4. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.;Fabbri;JAMA,2011

5. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.;Zenz;Blood,2009

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated MicroRNAs in Chronic Lymphocytic Leukemia;Cureus;2024-09-06

2. MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells;Cancer Cell International;2024-07-18

3. Multiple omics levels of chronic lymphocytic leukemia;Cell Death Discovery;2024-06-21

4. miRNA Biology in Chronic Lymphocytic Leukemia;Seminars in Hematology;2024-06

5. An overview of prognostic markers in patients with CLL;Frontiers in Oncology;2024-05-16